APO Research
Talk to an analyst

APO RESEARCH · REPORT

Focal Segmental Glomerulosclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Focal Segmental Glomerulosclerosis Drug Industry Growth and Trends Forecast to 2032

22 December 202593 pages

Choose your research edition.

Industry ResearchFocal Segmental Glomerulosclerosis Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Focal Segmental Glomerulosclerosis Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Focal Segmental Glomerulosclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Focal Segmental Glomerulosclerosis Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Focal Segmental Glomerulosclerosis Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Focal Segmental Glomerulosclerosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Focal Segmental Glomerulosclerosis Drug include Takeda, GlaxoSmithKline Plc, Variant Pharmaceuticals Inc, Retrophin Inc, Dimerix Bioscience Pty Ltd and Complexa Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Focal Segmental Glomerulosclerosis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Focal Segmental Glomerulosclerosis Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Focal Segmental Glomerulosclerosis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Focal Segmental Glomerulosclerosis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Focal Segmental Glomerulosclerosis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Focal Segmental Glomerulosclerosis Drug Market by Company

Takeda

GlaxoSmithKline Plc

Variant Pharmaceuticals Inc

Retrophin Inc

Dimerix Bioscience Pty Ltd

Complexa Inc

Focal Segmental Glomerulosclerosis Drug Segment by Type

Losmapimod

SHP-627

Sparsentan

TM-5484

Others

Focal Segmental Glomerulosclerosis Drug Segment by Application

Clinic

Hospital

Research Center

Others

Focal Segmental Glomerulosclerosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Focal Segmental Glomerulosclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Focal Segmental Glomerulosclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Focal Segmental Glomerulosclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Focal Segmental Glomerulosclerosis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Focal Segmental Glomerulosclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Losmapimod Table 2. Major Company of SHP-627 Table 3. Major Company of Sparsentan Table 4. Major Company of TM-5484 Table 5. Major Company of Others Table 6. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 8. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Focal Segmental Glomerulosclerosis Drug Price by Type (2021-2026) & (US$/unit) Table 12. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2027-2032) & (k units) Table 13. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Focal Segmental Glomerulosclerosis Drug Price by Type (2027-2032) & (US$/unit) Table 17. North America Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 18. North America Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 20. Europe Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 24. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Focal Segmental Glomerulosclerosis Drug Industry Trends Table 28. Focal Segmental Glomerulosclerosis Drug Industry Drivers Table 29. Focal Segmental Glomerulosclerosis Drug Industry Opportunities and Challenges Table 30. Focal Segmental Glomerulosclerosis Drug Industry Restraints Table 31. Global Focal Segmental Glomerulosclerosis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Company (2021-2026) Table 33. Global Focal Segmental Glomerulosclerosis Drug Sales by Company (2021-2026) & (k units) Table 34. Global Focal Segmental Glomerulosclerosis Drug Sales Share by Company (2021-2026) Table 35. Global Focal Segmental Glomerulosclerosis Drug Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Focal Segmental Glomerulosclerosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Focal Segmental Glomerulosclerosis Drug Major Company Production Sites and Headquarters Table 38. Global Focal Segmental Glomerulosclerosis Drug Company, Product Type & Application Table 39. Global Focal Segmental Glomerulosclerosis Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Focal Segmental Glomerulosclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Focal Segmental Glomerulosclerosis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2026) & (k units) Table 44. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Focal Segmental Glomerulosclerosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2027-2032) & (k units) Table 49. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Focal Segmental Glomerulosclerosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 55. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Focal Segmental Glomerulosclerosis Drug Price by Application (2021-2026) & (US$/unit) Table 59. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2027-2032) & (k units) Table 60. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Focal Segmental Glomerulosclerosis Drug Price by Application (2027-2032) & (US$/unit) Table 64. North America Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 65. North America Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 67. Europe Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 71. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Takeda Company Information Table 75. Takeda Business Overview Table 76. Takeda Focal Segmental Glomerulosclerosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Takeda Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 78. Takeda Recent Development Table 79. GlaxoSmithKline Plc Company Information Table 80. GlaxoSmithKline Plc Business Overview Table 81. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 83. GlaxoSmithKline Plc Recent Development Table 84. Variant Pharmaceuticals Inc Company Information Table 85. Variant Pharmaceuticals Inc Business Overview Table 86. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 88. Variant Pharmaceuticals Inc Recent Development Table 89. Retrophin Inc Company Information Table 90. Retrophin Inc Business Overview Table 91. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 93. Retrophin Inc Recent Development Table 94. Dimerix Bioscience Pty Ltd Company Information Table 95. Dimerix Bioscience Pty Ltd Business Overview Table 96. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 98. Dimerix Bioscience Pty Ltd Recent Development Table 99. Complexa Inc Company Information Table 100. Complexa Inc Business Overview Table 101. Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Complexa Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 103. Complexa Inc Recent Development Table 104. North America Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 105. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 106. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2026) Table 107. North America Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 108. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 109. North America Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 110. North America Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 111. North America Focal Segmental Glomerulosclerosis Drug Market Share by Country (2021-2026) Table 112. North America Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 113. North America Focal Segmental Glomerulosclerosis Drug Market Share Forecast by Country (2027-2032) Table 114. Europe Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 115. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 116. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2026) Table 117. Europe Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 118. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 119. Europe Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. Europe Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 121. Europe Focal Segmental Glomerulosclerosis Drug Market Share by Country (2021-2026) Table 122. Europe Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. Europe Focal Segmental Glomerulosclerosis Drug Market Share Forecast by Country (2027-2032) Table 124. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 125. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 126. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2026) Table 127. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 128. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 131. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Share by Country (2021-2026) Table 132. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Share Forecast by Country (2027-2032) Table 134. Latin America Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 135. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 136. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2026) Table 137. Latin America Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 138. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 139. Latin America Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Latin America Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 141. Latin America Focal Segmental Glomerulosclerosis Drug Market Share by Country (2021-2026) Table 142. Latin America Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Latin America Focal Segmental Glomerulosclerosis Drug Market Share Forecast by Country (2027-2032) Table 144. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 146. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2026) Table 147. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032) & (k units) Table 148. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Share by Country (2021-2026) Table 152. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Share Forecast by Country (2027-2032) Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Focal Segmental Glomerulosclerosis Drug Distributors List Table 157. Focal Segmental Glomerulosclerosis Drug Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Focal Segmental Glomerulosclerosis Drug Image Figure 2. Global Focal Segmental Glomerulosclerosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Focal Segmental Glomerulosclerosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Focal Segmental Glomerulosclerosis Drug Sales (2021-2032) & (k units) Figure 5. Losmapimod Image Figure 6. Global Losmapimod Sales YoY Growth (2021-2032) & (k units) Figure 7. SHP-627 Image Figure 8. Global SHP-627 Sales YoY Growth (2021-2032) & (k units) Figure 9. Sparsentan Image Figure 10. Global Sparsentan Sales YoY Growth (2021-2032) & (k units) Figure 11. TM-5484 Image Figure 12. Global TM-5484 Sales YoY Growth (2021-2032) & (k units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Focal Segmental Glomerulosclerosis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Focal Segmental Glomerulosclerosis Drug Market Share by Type 2025 VS 2032 Figure 17. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Focal Segmental Glomerulosclerosis Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 33. Research Center Image Figure 34. Global Research Center Sales YoY Growth (2021-2032) & (k units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 37. Global Focal Segmental Glomerulosclerosis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Focal Segmental Glomerulosclerosis Drug Market Share by Application 2025 VS 2032 Figure 39. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Focal Segmental Glomerulosclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. North America Focal Segmental Glomerulosclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Focal Segmental Glomerulosclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Europe Focal Segmental Glomerulosclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Focal Segmental Glomerulosclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Latin America Focal Segmental Glomerulosclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Focal Segmental Glomerulosclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Focal Segmental Glomerulosclerosis Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Focal Segmental Glomerulosclerosis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Losmapimod
  • SHP-627
  • Sparsentan
  • TM-5484
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Takeda
  • GlaxoSmithKline Plc
  • Variant Pharmaceuticals Inc
  • Retrophin Inc
  • Dimerix Bioscience Pty Ltd
  • Complexa Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Focal Segmental Glomerulosclerosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Focal Segmental Glomerulosclerosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Focal Segmental Glomerulosclerosis Drug Market by Type
  6. 1.3.1 Losmapimod
  7. 1.3.2 SHP-627
  8. 1.3.3 Sparsentan
  9. 1.3.4 TM-5484
  10. 1.3.5 Others
  11. 1.4 Global Focal Segmental Glomerulosclerosis Drug Market Size by Type
  12. 1.4.1 Global Focal Segmental Glomerulosclerosis Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Focal Segmental Glomerulosclerosis Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Focal Segmental Glomerulosclerosis Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Focal Segmental Glomerulosclerosis Drug Industry Trends
  2. 2.2 Focal Segmental Glomerulosclerosis Drug Industry Drivers
  3. 2.3 Focal Segmental Glomerulosclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Focal Segmental Glomerulosclerosis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Focal Segmental Glomerulosclerosis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Focal Segmental Glomerulosclerosis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Focal Segmental Glomerulosclerosis Drug Price (2021-2026)
  4. 3.4 Global Focal Segmental Glomerulosclerosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Focal Segmental Glomerulosclerosis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Focal Segmental Glomerulosclerosis Drug Company, Product Type & Application
  7. 3.7 Global Focal Segmental Glomerulosclerosis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Focal Segmental Glomerulosclerosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Focal Segmental Glomerulosclerosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Focal Segmental Glomerulosclerosis Drug Tier 1, Tier 2, and Tier 3
4 Focal Segmental Glomerulosclerosis Drug Regional Status and Outlook
  1. 4.1 Global Focal Segmental Glomerulosclerosis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Focal Segmental Glomerulosclerosis Drug Historic Market Size by Region
  3. 4.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Focal Segmental Glomerulosclerosis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Focal Segmental Glomerulosclerosis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Focal Segmental Glomerulosclerosis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Focal Segmental Glomerulosclerosis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Focal Segmental Glomerulosclerosis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Focal Segmental Glomerulosclerosis Drug by Application
  1. 5.1 Focal Segmental Glomerulosclerosis Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.1.4 Others
  6. 5.2 Global Focal Segmental Glomerulosclerosis Drug Market Size by Application
  7. 5.2.1 Global Focal Segmental Glomerulosclerosis Drug Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Focal Segmental Glomerulosclerosis Drug Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Focal Segmental Glomerulosclerosis Drug Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Focal Segmental Glomerulosclerosis Drug Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 GlaxoSmithKline Plc
  8. 6.2.1 GlaxoSmithKline Plc Company Information
  9. 6.2.2 GlaxoSmithKline Plc Business Overview
  10. 6.2.3 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  12. 6.2.5 GlaxoSmithKline Plc Recent Developments
  13. 6.3 Variant Pharmaceuticals Inc
  14. 6.3.1 Variant Pharmaceuticals Inc Company Information
  15. 6.3.2 Variant Pharmaceuticals Inc Business Overview
  16. 6.3.3 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  18. 6.3.5 Variant Pharmaceuticals Inc Recent Developments
  19. 6.4 Retrophin Inc
  20. 6.4.1 Retrophin Inc Company Information
  21. 6.4.2 Retrophin Inc Business Overview
  22. 6.4.3 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  24. 6.4.5 Retrophin Inc Recent Developments
  25. 6.5 Dimerix Bioscience Pty Ltd
  26. 6.5.1 Dimerix Bioscience Pty Ltd Company Information
  27. 6.5.2 Dimerix Bioscience Pty Ltd Business Overview
  28. 6.5.3 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product Portfolio
  30. 6.5.5 Dimerix Bioscience Pty Ltd Recent Developments
  31. 6.6 Complexa Inc
  32. 6.6.1 Complexa Inc Company Information
  33. 6.6.2 Complexa Inc Business Overview
  34. 6.6.3 Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Complexa Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  36. 6.6.5 Complexa Inc Recent Developments
7 North America by Country
  1. 7.1 North America Focal Segmental Glomerulosclerosis Drug Sales by Country
  2. 7.1.1 North America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Focal Segmental Glomerulosclerosis Drug Market Size by Country
  6. 7.2.1 North America Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Focal Segmental Glomerulosclerosis Drug Sales by Country
  2. 8.1.1 Europe Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Focal Segmental Glomerulosclerosis Drug Market Size by Country
  6. 8.2.1 Europe Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Focal Segmental Glomerulosclerosis Drug Sales by Country
  2. 10.1.1 South America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Focal Segmental Glomerulosclerosis Drug Market Size by Country
  6. 10.2.1 South America Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Focal Segmental Glomerulosclerosis Drug Value Chain Analysis
  2. 12.1.1 Focal Segmental Glomerulosclerosis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Focal Segmental Glomerulosclerosis Drug Production Mode & Process
  7. 12.2 Focal Segmental Glomerulosclerosis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Focal Segmental Glomerulosclerosis Drug Distributors
  10. 12.2.3 Focal Segmental Glomerulosclerosis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst